Assessments of Anxiety and Depression in US Adult People With P-W-171 Hemophilia Across Patient-Reported Outcomes in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study

Michael Recht,¹ Katharine Batt,² Michelle Witkop,³ Robert Z. Gut,⁴ David L. Cooper,⁴ Christine L. Kempton⁵ ¹Oregon Health & Science University, Portland, OR; ²Wake Forest School of Medicine, Winston-Salem, NC; ³Munson Medical Center, Traverse City, MI; ⁴Novo Nordisk Inc., Clinical, Medical, and Regulatory Affairs, Plainsboro, NJ; ⁵Emory University School of Medicine, Atlanta, GA.


instruments in adults with hemophilia


- joint disease associated with recurrent hemarthrosis
- addressed
- questionnaire,² and in 37% of PWH as assessed by PHQ9³
- identified in approximately 50% of PWH⁴

- instruments
- (VAS) and SF-36v2

- or B (23%); 9% had inhibitors
- employed (77%); 65% were married or had a long-term partner
- overweight/obese, and 65% self-reported arthritis/bone/joint problems
- antidepressants
- reported anxiety, 26% were receiving anxiolytics

- are presented in Figure 1







0% 10%

References

Conflict of interest disclosure

- in Newtown, PA.

Conclusions

P-FiQ highlights the high prevalence of emotional issues faced by adult PWH, as identified across PRO instruments with varying time scales of assessment

The results of this study underscore the importance of including validated measures of anxiety and depression (eg, GAD7 and PHQ9) in future research studies, as well as the need for more consistent clinical assessments and patient dialogue regarding anxiety/depression in PWH

During the past 4 weeks, 59% experienced physical/emotional problems that interfered with normal social activities (12% most or all of the time and 17% quite a bit or extremely) (Figure 6)

Figure 6 SF-36v2 – impact of physical and emotional problems on social activities (over the past 4 weeks)

Interference with social activities

	24.9			22.3		40.4			
	1	I	1	1	1	1	1	1]
%	20%	30%	40%	50%	60%	70%	80%	90%	100%

■ All of the time ■ Most of the time ■ Some of the time ■ A little of the time ■ None of the time ■ Missing

Extent of interference with normal social activities

40.4				27.3			5.0	12.3	4.2
%	20%	30%	40%	50%	60%	70%	80%	90%	100%
■Not at all ■Slightly ■N				Noderately Quite a bit			Extremely Missing		

1. Miners A et al. *Haemophilia*. 1999;5(6):378-385.

2. Barlow J et al. Haemophilia. 2007;68(3):235-242.

3. lannone M et al. Haemophilia. 2012;18(6):868-874.

4. Molleman E, Knippenberg A. Patient Educ Couns. 1987;10:175-189.

M. Recht has received grant/research support from Baxter, Biogen Idec, Novo Nordisk, and Pfizer and served as a consultant to Kedrion and Novo Nordisk. K. Batt is a shareholder of Merck and Sanofi and has received grant/research support from Novo Nordisk. M. Witkop has received grant funding from Pfizer, is on advisory boards with Baxter BioScience, CSL Behring, Novo Nordisk, Octapharma, and Pfizer, and is on the speakers bureau at Novo Nordisk. R. Gut is an employee of Novo Nordisk Inc. D. Cooper is an employee of Novo Nordisk Inc. C. Kempton has served as a consultant for Baxalta, Biogen, CSL Behring, Hoffman La-Roche, and Kedrion and received grant/research support from Novo Nordisk.

This trial was sponsored by Novo Nordisk Inc. and is registered with ClinicalTrials.gov (NCT01988532). The authors acknowledge the medical writing assistance of Anna Abt, PhD, and Kathryn Kidd, PhD, of ETHOS Health Communications

Presented at the World Federation of Hemophilia (WFH) World Congress, July 24-28, 2016, Orlando, FL, USA.









